tbuckley/cabot-search huggingface dataset:
Macrophage PPARγ, a Lipid Activated Transcription Factor Controls the Growth Factor GDF3 and Skeletal Muscle Regeneration
Authors: Tamas Varga, Rémi Mounier, Andreas Patsalos, Péter Gogolák, Matthew Peloquin, Attila Horvath, Attila Pap, Bence Daniel, Gergely Nagy, Eva Pintye, Szilárd Poliska, Sylvain Cuvellier, Sabrina Ben Larbi, Brian E. Sansbury, Matthew Spite, Chester W. Brown, Bénédicte Chazaud, Laszlo Nagy
Journal: Immunity (2016)
SP0026 The Basics of A Regression Analysis
Authors: S. Norton
Journal: Annals of the Rheumatic Diseases (2016)

The aim of this presentation is to provide a brief introduction to the basics of the regression model. This model provides the foundation of modern statistical modelling and allows us to assess whether a variable, or range of variables, is associated with an outcome variable. Extrapolating from the model we can develop predictions about the level of an outcome variable, such as disease outcome, based on the values of predictive variables. The underlying equation, meaning of key terms and basic diagnostics to determine the robustness of inference from a regression model will be explained. <h3>Disclosure of Interest</h3> None declared
Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials
Authors: Shaji Kumar, Lijun Zhang, Angela Dispenzieri, Sagar Lonial, Rafat Abonour, Leonard Heffner, Natalie Scott Callander, David Siegel, Morie Gertz, Robert Kyle, Philip R. Greipp, S. Vincent Rajkumar
Journal: Blood (2008)
Endothelial Injury Is Common in Antiphospholipid-Positive Patients but Risk of Thrombosis Depends on Platelet Activation.
Authors: Julio A. Chirinos, Maike Tiede, Wenche Jy, Carlos J. Bidot, Lawrence L. Horstman, Joaquin J. Jimenez, Eugene R. Ahn, Yeon S. Ahn
Journal: Blood (2004)
P1190 : The role of NKT cells in a mouse model (NOD.C3C4) with spontaneous bile duct inflammation
Authors: E. Schrumpf, X. Jiang, S. Zeissig, M.J. Pollheimer, J.A. Anmarkrud, C. Tan, M.A. Exley, T.H. Karlsen, R.S. Blumberg, E. Melum
Journal: Journal of Hepatology (2015)
Autoantibodies Specific to hnRNP K: A New Diagnostic Marker for Immune Pathophysiology in Bone Marrow Failure Syndromes.
Authors: Zhirong Qi, Hiroyuki Takamatsu, Xuzhang Lu, J. Luis Espinoza, Naomi Sugimori, Kanako Mochizuki, Shinji Nakao
Journal: Blood (2008)
Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.
Authors: Michael R. Grever, David M. Lucas, Gordon W. Dewald, Donna S. Neuberg, Ian W. Flinn, Martin S. Tallman, John G. Gribben, John C. Byrd
Journal: Blood (2004)
Streptamer Technology for the Assessment of CMVpp65 Specific CD8+ T Cell Frequencies and for the Adoptive T Cell Transfer to Post-Transplant Patients.
Authors: Anita Schmitt, Junxia Yao, Hermann Einsele, Ulrich Grigoleit, Dirk Busch, Manuel Odendahl, Lothar Germeroth, Torsten Tonn, Markus Wiesneth, Markus Rojewski, Clemens Bechter, Stefanie von Harsdorf, Hartmut Dohner, Donald Bunjes, Michael Schmitt
Journal: Blood (2007)
PTU-073 In Patients with IBD Switching from Originator Infliximab (Remicade) to Biosimilar Infliximab (CT-P13) Is Safe and Effective
Authors: S Rahmany, S Cotton, S Garnish, M Brown, R Saich, D Lloyd, JN Gordon
Journal: Gut (2016)

<h3>Introduction</h3> Biosimilar infliximab (CT-P13) has been licensed for the treatment of IBD in Europe for over a year with the potential for significant cost savings. However, uptake in the UK has been slow primarily due to concerns over the lack of safety and efficacy data particularly with regard to switching patients from the originator product. We present the preliminary data from a controlled switch programme in a cohort of adult IBD patients. <h3>Methods</h3> A prospective study was undertaken to assess the safety and efficacy of switching patients receiving originator infliximab (Remicade) to its biosimilar (CT-P13). Patient demographic data was collected along with disease severity scores (HBI and SCCAI), biological markers of disease activity, drug and antibody levels and PROM data (IBD-Control questionnaire) prior to the switch and at each subsequent infusion visit. Evaluation of the efficacy of biosimilar infliximab at the time of the last infusion was compared with the originator at switch over. Means, medians, and ranges were calculated. Adverse events were prospectively collected. <h3>Results</h3> 78 IBD patients were included in the cohort (63 CD and 15 UC). The average age for the CD and UC patients was 43 and 42 years respectively. The average length of therapy on Remicade prior to the switch was 46 months for CD and 25 months for UC. 66/78 (85%) patients were receiving the standard dosage of 5 mg/kg 8 weekly with 12/78 (15%) either on a shortened interval or a 10 mg/kg dose. 42/63 (67%) of CD patients were in remission at switch over compared to 43/60 (72%) at the most recent infusion (4–6 months). The number of patients with mild, moderate and severe disease remained stable throughout the study period (Mild 10/63 (16%) v 11/60 (18%): Moderate 10/63 (16%) v 5/60 (8%): Severe 1/63 (2%) v 1/60 (2%)). 9/15 (60%) of UC patients were in remission at switch over compared with 11/13 (85%) at the most recent infusion. There was no difference in the mean CRP before and after the switch in either CD patients (5.4 vs 5.6 p=0.32) or UC patients (3.1 vs 3.0 p=0.73). The mean patient questionnaire score data also remained unchanged before and after the switch (CD 4.4 vs 4.0 p=0.56, UC 4.9 vs 3.1 p=0.61). Five patients (3 CD, 2 UC) discontinued infliximab during the study period (3 switched biological class, 1 infusion reaction, 1 deep remission). There were no adverse safety signals with one infusion reaction (1/283 infusions) and the rate of mild adverse events unchanged from before and after the switch. <h3>Conclusion</h3> Switching patients with IBD from originator infliximab to biosimilar infliximab appears both safe and effective. Wider uptake in the UK would result in considerable cost savings to the NHS. <h3>Disclosure of Interest</h3> None Declared
Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria
Authors: Janine Gericke, Martin Metz, Tatevik Ohanyan, Karsten Weller, Sabine Altrichter, Per Stahl Skov, Sidsel Falkencrone, Janko Brand, Arno Kromminga, Tomasz Hawro, Martin K. Church, Marcus Maurer
Journal: Journal of Allergy and Clinical Immunology (2016)
AB0839 Fibromyalgia Syndrome in Pregnant Women; The Effects on Physical Functioning and Psychological Status
Authors: H. Genc, M. Atasever, B. Duyur Cakit, M. Seval, A. Koc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There are many unexplored issues related to the presence of fibromyalgia syndrome (FS) in pregnancy such as prevalence of FS, most common symptoms, the impact of FS on physical functioning, psychological status, and treatment of a fibromyalgic pregnant <h3>Objectives</h3> To investigate the frequency and most common symptoms of FS among pregnant woman and determine the impacts of FS on physical functioning and psychological status in those patients. <h3>Methods</h3> A total of 360 pregnants in the third trimester of pregnancy were included in the study. The pregnants were split into two groups in terms of having or not having FS. Group 1 was consisted of 136 pregnant women with FS. 224 pregnant women without FS were formed control group (group 2). The presence of fibromyalgia was investigated via 2010 ACR classification criteria. Widespread pain index and symptom severity scores of the patients were recorded. The impact of FS on physical functions was evaluated using fibromyalgia impact questionnaire. Psychological status of the patients were evaluated using state-trait anxiety inventory, the Wijma delivery expectancy/experience questionnaire and Beck depression inventory. <h3>Results</h3> 136 of 360 pregnants (37.7%) had FS. Mean ages of the 136 pregnants with FS was 27 years and of the 224 without FS was 26.5 years (p&gt;0.05). Low back pain is the most common complaint and fatique is the most common symptom in pregnants group with FS. Compared with the pregnants group without FS, pregnants group with FS had higher values of pain severity and higher levels of physical disability (p&lt;0.001). Pregnants group with FS had also higher values of anxiety, fear of childbirth and depression (p&lt;0.001, for all values). Symptom severity score and physical impairment score were found to be significantly correlated with increased levels of pain, depression, anxiety, fear of childbirth, fatique, increased scores of waking unrefreshed, cognitive symptoms and increased rate of low back pain (p&lt;0.001 for all values). <h3>Conclusions</h3> FS is common among pregnant women and the existence of FS in pregnancy is a severe factor for maternal stres, anxiety and depression. If we desire a healthy pregnancy and a good child outcome, we need to get therapeutic measures for fibromyalgia syndrome. <h3>Disclosure of Interest</h3> None declared
Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study
Authors: Kadee J Raser, Gregory A. Yanik, John M. Magenau, Steven C. Goldstein, Attaphol Pawarode, Carrie Kitko, John E. Levine, David Hanauer, Daniel R. Couriel
Journal: Blood (2013)
Cost-effectiveness of Wait Time Reduction for Intensive Behavioral Intervention Services in Ontario, Canada
Authors: Caroline Piccininni, Lise Bisnaire, Melanie Penner
Journal: JAMA Pediatrics (2016)

<h3>Importance</h3> Earlier access to intensive behavioral intervention (IBI) is associated with improved outcomes for children with severe autism spectrum disorder (ASD); however, there are long waiting times for this program. No analyses have been performed modeling the cost-effectiveness of wait time reduction for IBI. <h3>Objectives</h3> To model the starting age for IBI with reduced wait time (RWT) (by half) and eliminated wait time (EWT), and perform a cost-effectiveness analysis comparing RWT and EWT with current wait time (CWT) from government and societal perspectives. <h3>Design, Setting, and Participants</h3> Published waiting times were used to model the mean starting age for IBI for CWT, RWT, and EWT in children diagnosed with severe ASD who were treated at Ontario's Autism Intervention Program. Inputs were loaded into a decision analytic model, with an annual discount rate of 3% applied. Incremental cost-effectiveness ratios (ICERs) were determined. One-way and probabilistic sensitivity analyses were performed to assess the effect of model uncertainty. We used data from the year 2012 (January 1 through December 31) provided from the Children's Hospital of Eastern Ontario IBI center for the starting ages. Data analysis was done from May through July 2015. <h3>Main Outcomes and Measures</h3> The outcome was independence measured in dependency-free life-years (DFLYs) to 65 years of age. To derive this, expected IQ was modeled based on probability of early (age &lt;4 years) or late (age ≥4 years) access to IBI. Probabilities of having an IQ in the normal (≥70) or intellectual disability (&lt;70) range were calculated. The IQ strata were assigned probabilities of achieving an independent (60 DFLYs), semidependent (30 DFLYs), or dependent (0 DFLYs) outcome. Costs were calculated for provincial government and societal perspectives in Canadian dollars (Can$1 = US$0.78). <h3>Results</h3> The mean starting ages for IBI were 5.24 years for CWT, 3.89 years for RWT, and 2.71 years for EWT. From the provincial government perspective, EWT was the dominant strategy, generating the most DFLYs for Can$53 000 less per individual to 65 years of age than CWT. From the societal perspective, EWT produced lifetime savings of Can$267 000 per individual compared with CWT. The ICERs were most sensitive to uncertainty in the starting age for IBI and in achieving a normal IQ based on starting age. <h3>Conclusions and Relevance</h3> This study predicts the long-term effect of the current disparity between IBI service needs and the amount of IBI being delivered in the province of Ontario. The results suggest that providing timely access optimizes IBI outcomes, improves future independence, and lessens costs from provincial and societal perspectives.
Gain-of-Phosphorylation Mutations in Coiled-Coil and DNA-Binding Domain of STAT1 Identified in Japanese Patients with Chronic Mucocutaneous Candidiasis
Authors: Yoko Mizoguchi, Satoshi Okada, Miyuki Tsumura, Osamu Hirata, Jean-Laurent Casanova, Tomohiro Morio, Masao Kobayashi
Journal: Blood (2012)
An Inconvenient Truth Regarding Operative Emergencies in General Surgery
Authors: Richard P. G. ten Broek, Harry van Goor
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Pre-B Cell Receptor Signaling Prevents Leukemic Transformation by BCR-ABL1
Authors: Daniel Trageser, Cihangir Duy, Lars Klemm, Tanja Gruber, Rahul Nahar, Eugene Park, Yong-mi Kim, John Groffen, Nora Heisterkamp, Wolf-Karsten Hofmann, Giovanni Martinelli, Richard T Williams, Hassan Jumaa, Markus Muschen
Journal: Blood (2008)
Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).
Authors: Julie A. Wojtaszczyk, Theresa Hahn, Minoo Battiwalla, Maria R. Baer, Eunice Wang, Maurice Barcos, Barbara Bambach, Swaminathan Padmanabhan, Meir Wetzler, Philip L. McCarthy
Journal: Blood (2006)
A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.
Authors: Ashutosh D Wechalekar, Nancy L Wassef, Simon DJ Gibbs, Julian Gillmore, Felicia Dike, Helen Lachmann, Prayman Sattianayagam, Arthur Bradwell, Philip N Hawkins
Journal: Blood (2009)
Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial
Authors: Jose F. Tomas, Carlos Montalbán, Joaquín Martínez-López, Alberto Fernández de Sevilla, Nicolás Díaz, Miguel Canales, Rafael Martínez, Pedro Sánchez-Godoy, María Dolores Caballero, Javier Peñalver, Elena Prieto, Antonio Salar, Carmen Burgaleta, José A. Queizán, Roberto Bajo, Pilar Bravo, Carmen Cabrera, Doleres Monteagudo, Antonio Paz, María Jesús Peñarrubia, Javier de la Serna
Journal: Blood (2007)
SAT0210 Hierarchical Cluster Study of Patients with Anti-KU Antibodies Identifies Two Phenotypical Subgroups with Distinct Prognosis Recognized by Anti-DNA Status
Authors: L. Spielman, M. Schaeffer, J. Goetz, T. Martin, J. Sibilia, A. Meyer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The presence of anti-Ku antibody is associated with a wide variety of clinical manifestations and various outcomes. <h3>Objectives</h3> We attended to refine anti-Ku associated disease by identifying subgroups of Ku-positive patients with similar clinico-biological features and prognosis. <h3>Methods</h3> We reviewed clinical, biological characteristics, diagnosis and management of 24 patients with anti-Ku antibody. A multidimensional analyze was performed to highlight homogeneous groups of patients. We search for features that most strongly match with each group. <h3>Results</h3> Anti-Ku positive patients had joint (n=19), muscle (n=10), lung (n=9), skin (n=9), renal (n=9), hematological (n=8), thrombotic (n=6), serous (n=6) and gastrointestinal (n=4) involvements. Associated antibodies were anti-DNA (n=7), -SSA (n=6), -RNP (n=4), -SSB (n=1), -Sm (n=1), rheumatoid factor (n=9) and ACPA (n=4). Diagnosis were overlap myositis (n=9), lupus erythematosus (n=8), Sjögren9s syndrome (n=7), rheumatoid arthritis (n=3), undifferentiated connective (n=2), and systemic sclerosis (n=2). Many patients had criteria for several connectivite tissue diseases. Managements were heterogeneous. Multidimensional analyze identified to groups that were mutually exclusive: (i) Patients characterized by scleroderma-like skin disease,myositis and ILD,frequently treated with high dose of corticosteroids, (ii) Patients with lupus like skin disease, haematological and renal involvements frequently receiving cyclophosphamide and mycophenolate mofetil. Anti-DNA antibody, absent in the first group and present in the second was the most powerful criteria to distinguish these two subsets of the anti-ku associated disease (sensibility 93% and a sensitivity of 86%). <h3>Conclusions</h3> Anti-DNA status distinguishes patients at risk of muscle and lung involvement (anti-DNA negative) from patients at risk of renal involvement (anti-DNA positive). These data significantly refine anti-Ku associated disease and help to personalize monitoring and care of the patients. <h3>Disclosure of Interest</h3> None declared
FRI0335 An Evaluation of Clinical Outcome Measures for Musculoskeletal Lupus Using Ultrasound as A Gold Standard: Table 1
Authors: K. Mahmoud, A. Zayat, C.J. Edwards, M.Y. Md Yusof, H. Cassamoali, M. D'Agostino, P. Emery, E.M. Vital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Musculoskeletal symptoms in SLE patients are common, but difficult to assess clinically. Ultrasound (US) is an objective measure of synovitis. <h3>Objectives</h3> To test clinical tools currently used for musculoskeletal lupus against US as a gold standard. <h3>Methods</h3> A multicentre cross-sectional study recruited 107 patients in Leeds and Southampton fulfilling ACR/SLICC criteria for SLE, all had history of musculoskeletal symptoms and 79% had pain at the time of evaluation. Patients with positive CCP or RF were excluded. Patients were clinically assessed using BILAG, SLEDAI, tender joint count (TJC), swollen joint count (SJC), physician and patient VAS (both 0–100, for MSK symptoms). US hand was used to examine joints and tendon sheaths. <h3>Results</h3> There was disagreement between US and clinical joint swelling in 26% of patients. In the 40% with clinical joint swelling, US confirmed this in 83%. 20% of all patients had US synovitis that was not detected clinically. Overall, objective synovitis was found in 40% of patients using clinical swelling and 53% using US. US was correlated with SJC (R=0.389, P≤0.001), MSK-BILAG numeric score (R=0.503, P≤0.001), and physician VAS (R=0.5, P≤0.001), but not with TJC, SLEDAI, or patient VAS. We then looked for clinical appearance of patients with US-proven synovitis: see table 1. We identified significant associations in the whole cohort. In multivariate analysis only physician-VAS was significant (p=0.018). However, in 50 patients with no joint swelling, 15 had US synovitis, but no clinical variable could identify this. <h3>Conclusions</h3> Swollen Joint Count, Physician VAS, and MSK-BILAG all correlate with true synovitis as defined by US. However, these variables are all based on the clinical detection of joint swelling and 50% of this cohort did not have joint swelling. In the latter group, no clinical variable was helpful in identifying the 30% of patients with US-proven synovitis. US should be used to evaluate MSK-SLE patients who do not have clinical synovitis. <h3>Disclosure of Interest</h3> None declared
FRI0055 Sp1 Inhibitor Modulates The Autocrine Action of Gliostatin/Thymidine Phosphorylase (GLS/TYMP) in Rheumatoid Fibroblast-like Synoviocytes
Authors: N. Tatematsu, Y. Waguri-Nagaya, Y. Kawaguchi, K. Ikuta, M. Kobayashi, M. Nozaki, K. Asai, M. Aoyama, T. Otsuka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gliostatin/thymidine phosphorylase (GLS/TYMP) is known to have angiogenic and arthritogenic activities, and aberrant GLS production has been observed in the synovial membranes of rheumatoid arthritis (RA) patients. GLS induces its own expression in cultured fibroblast-like synoviocytes from RA patients (RA-FLSs). The promoters of GLS gene contain binding sites for the DNA binding protein Sp1. Previously, we have reported that the Sp1 transcription factor is essential for the expression of GLS in RA-FLSs and that the Sp1 inhibitor, mithramycin, inhibits the TNF-α-induced expression of GLS in cultured RA-FLSs. <h3>Objectives</h3> In this study we examined the inhibitory effect of the Sp1 inhibitor mithramycin on the autocrine activity of GLS expression induced by GLS in cultured RA-FLSs. <h3>Methods</h3> Samples of synovial tissue were obtained from 11 patients with RA who were undergoing total knee or elbow arthroplasty or arthroscopic synovectomy. RA-FLSs were cultured with GLS, with or without mithramycin. The expression levels of GLS were determined using reverse transcription-polymerase chain reactions (RT-PCR) and enzyme immunoassay. <h3>Results</h3> We investigated GLS mRNA and protein expressions in RA-FLSs treated with or without mithramycin, followed by incubation with GLS. Measuring GLS mRNA and protein levels showed significant induction by GLS alone compared with the control with no GLS. Pre-incubation with mithramycin significantly suppressed this induction. <h3>Conclusions</h3> The Sp1 inhibitor, mithramycin, down-regulated the increased expression of GLS in RA-FLSs treated with GLS. Because GLS plays a pathological role in RA, blocking GLS stimulation using mithramycin may suggest novel approaches to anti-rheumatic therapy. <h3>References</h3> Asai K, Hirano T, Matsukawa K, Kusada J, Takeuchi M, Otsuka T, Matsui N, Kato T. High concentrations of immunoreactive gliostatin/platelet-derived endothelial cell growth factor in synovial fluid and serum of rheumatoid arthritis. Clin Chim Acta 1993, 218:1–4. Waguri Y, Otsuka T, Sugimura I, Matsui N, Asai K, Moriyama A, Kato T. Gliostatin/platelet-derived endothelial cell growth factor as a clinical marker of rheumatoid arthritis and its regulation in fibroblast-like synoviocytes. Br J Rheumatol 1997, 36:315–321. Ikuta K, Waguri-Nagaya Y, Kikuchi K, Yamagami T, Nozaki M, Aoyama M, Asai K, Otsuka T. The Sp1 transcription factor is essential for the expression of gliostatin/thymidine phosphorylase in rheumatoid fibroblast-like synoviocytes. Arthritis Res Ther 2012, 14:R87. <h3>Acknowledgement</h3> This work was supported by the Japan Society for the Promotion of Science [Grant-in-Aid for Scientific Research (C) 26462309]. <h3>Disclosure of Interest</h3> None declared
Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL)
Authors: Andrew Hodson, Silvia Montoto, Naheed Mir, Antonio Pagliuca, Kate Cwynarski, Kirit M Ardeshna, Thurai Kumaran, Estella Matutes, Graham Talyor, Paul Fields
Journal: Blood (2010)
Overexpression of Her-2/neu Is Observed in One Third of Adult B-ALL Patients and Is Associated with Chemoresistance in These Patients.
Authors: Patrice Chevallier, Nelly Robillard, Soraya Wuilleme-Toumi, Anne-Sophie Guerin, Francoise Mechinaud, Jean-Luc Harousseau, Herve Avet-Loiseau
Journal: Blood (2004)